Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast CYTOGAM Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    CYTOGAM (Cytomegalovirus Immune Globulin) for CMV Prophylaxis After Transplantation

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and Part B coverage of physician-administered CYTOGAM IV infusion for CMV disease prevention after kidney, lung, liver, pancreas, or heart transplantation, subject to specialist, dosing, administration-site, and duration requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyCYTOGAM for CMV Prophylaxis After Transplantation
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 14, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming the transplant organ, CMV prophylaxis indication, specialist involvement, prescribed dose, administration setting, and post-transplant timing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    16 weeksMaximum coverage duration
    5Covered transplant organ types

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0850CYTOGAM HCPCS code
    2 CPTInfusion administration codes
    Not permittedReauthorization after coverage period

    Coverage Criteria

    Initial CYTOGAM Coverage

    Covered when ALL of the following requirements are met:

    ALL of the following

    • CYTOGAM is prescribed for prophylaxis of cytomegalovirus (CMV) disease associated with transplantation of a kidney, lung, liver, pancreas, or heart.
    • CYTOGAM is prescribed by, or in consultation with, an immunologist, nephrologist, pulmonologist, hepatologist, gastroenterologist, cardiologist, or transplant specialist.
    • The dose does not exceed the maximum dose indicated in the applicable dosing information and is consistent with FDA-approved labeling or accepted standards of medical practice.
    • CYTOGAM is administered by a physician through intravenous infusion in an office or hospital outpatient department (HOPD); self-administration is not permitted.
    • The member does not have a contraindication, including a history of severe hypersensitivity to cytomegalovirus immune globulin IV (human), other human immunoglobulin preparations, or any component of the formulation, or selective IgA deficiency.
    • The treatment follows LCD L34314 for Immune Globulin Intravenous (IVIG).

    Continuation and Reauthorization

    Continuation of CYTOGAM is subject to the following coverage limit:

    ALL of the following

    • Total CYTOGAM coverage is limited to 16 weeks post-transplantation.<= 16 weeks post-transplantation
    • Reauthorization beyond the permitted 16-week post-transplantation period is not permitted.

    Coverage for CYTOGAM is limited to a total of 16 weeks post-transplantation. Reauthorization beyond 16 weeks post-transplantation is excluded and is not permitted.

    CYTOGAM must be administered by a physician as an intravenous infusion in an office or hospital outpatient department (HOPD). CYTOGAM cannot be self-administered.

    Coding and Administration Details

    HCPCS CodeHCPCSCovered
    J0850Injection, cytomegalovirus immune globulin IV (human), per vial.
    CPT Procedural CodesCPTCovered
    96365Ther/proph/diag IV infusion, initial.
    96366Ther/proph/diag IV infusion, add-on.
    National Drug CodesNDCCovered
    70257-532-51CYTOGAM 10-digit NDC.
    70257-0532-51CYTOGAM 11-digit NDC.
    Post-transplant liver, pancreas, and heart dosing
    Initial dose150 mg/kg within 72 hours post-transplant
    2 weeks post-transplant100 mg/kg
    4 weeks post-transplant100 mg/kg
    6 weeks post-transplant100 mg/kg
    8 weeks post-transplant100 mg/kg to 150 mg/kg
    12 weeks post-transplant100 mg/kg
    16 weeks post-transplant100 mg/kg

    Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for physician-administered CYTOGAM IV infusion. CYTOGAM must be administered by a physician in an office or hospital outpatient department (HOPD) and cannot be self-administered.

    • Physician-administered IV infusion only
    • Site of care: physician office or HOPD
    • Self-administration is not permitted
    Documentation Required

    Required Clinical Documentation

    Submit clinical documentation demonstrating the transplant-related indication, specialist involvement, and proposed treatment regimen.

    • Transplantation of a covered organ: kidney, lung, liver, pancreas, or heart
    • CMV disease prophylaxis associated with the transplantation

    Clinical Background

    CYTOGAM is a human cytomegalovirus immune globulin containing standardized IgG antibodies to CMV. It is used for prophylaxis of CMV disease associated with transplantation of the kidney, lung, liver, pancreas, or heart. For organs other than the kidney, the covered-use description specifies a CMV-seropositive donor and CMV-seronegative recipient.

    Definitions

    Cytomegalovirus IVIG (CMV-IVIG)
    TermCytomegalovirus IVIG (CMV-IVIG)
    PreparationAn immunoglobulin G (IgG) preparation
    StandardizationContains a standardized amount of antibody to cytomegalovirus (CMV)
    Administration setting
    Administration methodPhysician-administered intravenous infusion
    Permitted settingsProvider office or hospital outpatient department
    Self-administrationNot permitted

    Initial Therapy

    Initial CYTOGAM Therapy

    Initial therapy requires all of the following:

    Initial therapy criteria

    • Covered CMV prophylaxis indication: CYTOGAM is used for prophylaxis of CMV disease associated with transplantation of the kidney, lung, liver, pancreas, or heart.

      For organs other than kidney, the covered-use description specifies a CMV-seropositive donor and CMV-seronegative recipient.

    • Authorized specialist involvement: CYTOGAM is prescribed by or in consultation with an immunologist, nephrologist, pulmonologist, hepatologist, gastroenterologist, cardiologist, or transplant specialist.
    • Physician-administered infusion: CYTOGAM is administered by physician-directed intravenous infusion in an office or hospital outpatient department.

      CYTOGAM cannot be self-administered.

    Continuation Therapy

    Continuation Therapy

    Continuation is permitted only within the initial post-transplant coverage period:

    Continuation requirements

    • Timing: Each subsequent CYTOGAM infusion occurs within 16 weeks post-transplantation.16 weeks post-transplantation

      Reauthorization beyond 16 weeks is not permitted.

    • Covered indication continues: CYTOGAM continues to be used for prophylaxis of CMV disease associated with transplantation of the kidney, lung, liver, pancreas, or heart.
    • Administration requirements continue: Each infusion is physician-administered intravenously in an office or hospital outpatient department.

    Quantity and Dose Limits

    CYTOGAM
    ProductCYTOGAM
    Maximum doseMust not exceed the dose indicated in the policy dosing schedule
    Additional dosing standardsMust also comply with FDA-approved labeling or accepted standards of medical practice

    Site of Care Requirements

    Billing Rule

    Administer CYTOGAM in the office

    In an office setting, CYTOGAM must be administered as a physician-administered IV infusion. It cannot be self-administered.

    • Administration site: provider office.
    • Administration method: physician-administered intravenous infusion.
    Billing Rule

    Administer CYTOGAM in hospital outpatient

    CYTOGAM may be administered as a physician-administered IV infusion in a hospital outpatient department. It cannot be self-administered.

    • Administration site: hospital outpatient department.
    • Administration method: physician-administered intravenous infusion.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyCYTOGAM for CMV Prophylaxis After Transplantation
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 14, 2026
    Last ReviewMay 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming the transplant organ, CMV prophylaxis indication, specialist involvement, prescribed dose, administration setting, and post-transplant timing.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Administration DetailsProvider RequirementsClinical BackgroundDefinitionsInitial TherapyContinuation TherapyQuantity and Dose LimitsSite of Care Requirements
    Kidney and lung transplant dosing
    Applicable transplantsKidney and lung transplantation
    Dose basisDose is based on the type of transplant
    Schedule detailThe source does not provide a complete separate kidney or lung dosing schedule
    Infusion rate
    Initial infusionStart at 15 mg/kg/hr
    First rate increaseAfter 30 minutes if tolerated, increase to 30 mg/kg/hr
    Maximum targetAfter another 30 minutes if tolerated, increase to a maximum target of 60 mg/kg/hr
    Subsequent doses15 mg/kg/hr for 15 minutes, then 30 mg/kg/hr for 15 minutes if tolerated, then a maximum of 60 mg/kg/hr; do not exceed 75 mL/hr
  1. Prescription by or consultation with an immunologist, nephrologist, pulmonologist, hepatologist, gastroenterologist, cardiologist, or transplant specialist
  2. Requested dose does not exceed the maximum dose indicated in the applicable dosing guidance
  3. Treatment follows FDA-approved labeling or accepted standards of medical practice and LCD L34314 for Intravenous Immune Globulin (IVIG)
  4. Denial Risk

    Coverage and Duration Requirements

    Coverage is limited to CMV prophylaxis associated with transplantation of a covered organ and is subject to dose and duration limits. Requests that do not meet these requirements, or that seek treatment beyond the allowed period, may be denied.

    • Covered transplant organs: kidney, lung, liver, pancreas, or heart
    • CMV prophylaxis must be associated with transplantation
    • Dose must not exceed the maximum dose indicated in the applicable dosing guidance
    • Total coverage duration is limited to 16 weeks post-transplantation
    • Reauthorization beyond 16 weeks is not permitted
    Denial Risk

    Contraindications

    CYTOGAM is not covered when the patient has a contraindication to cytomegalovirus immune globulin IV (human), other human immunoglobulin preparations, or a formulation component.

    • History of severe hypersensitivity to cytomegalovirus immune globulin IV (human), other human immunoglobulin preparations, or any component of the formulation
    • Selective IgA deficiency
  5. Dose within policy maximum: The prescribed dose does not exceed the maximum dose indicated in the applicable dosing regimen, FDA-approved labeling, or accepted standards of medical practice.
  6. Post-transplant coverage period: The initial course is provided within the authorized post-transplant coverage period.16 weeks post-transplantation

    Prophylactic CMV-IVIG should be considered in combination with ganciclovir. Reauthorization beyond 16 weeks is not permitted.

  7. CYTOGAM cannot be self-administered.

  8. Dose maximum continues: Each dose does not exceed the applicable maximum dose indicated in the dosing regimen, FDA-approved labeling, or accepted standards of medical practice.